权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Drug Delivery and Nanotechnology Module

药物输送和纳米技术模块

基本信息

批准号：
10020647
负责人：
Kannan Rangaramanujam
金额：
$ 7.78万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-07-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10020647
关键词：
Animal Model Animals Basic Science Biological Cell Culture Techniques Cells Clinical Research Collaborations Communities Core Grant Cultured Cells Development Devices Disease Doctor of Philosophy Dose Dose-Limiting Drug Delivery Systems Eye Faculty Gene Delivery Gene Expression Genes Genetic Engineering Glaucoma Grant Human In Vitro Institutes Legal patent Nanotechnology Nucleic Acids Optic Nerve Injuries Outcome Pathogenesis Pathway interactions Pharmaceutical Preparations Phenotype Proteins Publications Research Research Personnel Resources Retinopathy of Prematurity Services Site System Technology Therapeutic Therapeutic Effect Tissues Toxic effect Transfection United States National Institutes of Health Vision research Work base clinical translation drug discovery eye dryness imaging approach in vivo interest nanomedicine nanoparticle nanoscale novel imaging technology novel therapeutic intervention novel therapeutics particle pre-clinical ranpirnase small molecule targeted delivery therapeutic target tissue culture tool vector vision science

项目摘要

PROJECT SUMMARY – NANOTECHNOLOGY The Drug Delivery and Nanotechnology (DD&N) module is an enabling technology resource available to faculty of the Wilmer Eye Institute, by enabling sustained and targeted delivery of drugs administered intravitreally, subconjunctivally, or systemically, and in developing novel imaging technologies. During the current period, the collaborations have resulted many NIH grants, publications, many patents licensed, and significant translational efforts, with multiple therapeutic approaches developed by the Wilmer P30 team undergoing clinical translation. DD&N takes advantage of the expertise, technologies, and resources of the Wilmer Eye Institute’s Center for Nanomedicine (CNM). The Center for Nanomedicine at Wilmer serves as an anchor for the DD&N module, and has grown to seven faculty, collaborating with more than 15 faculty in Wilmer and more than 100 faculty across Johns Hopkins. Demand by Wilmer investigators (both established and early investigators) for the development and characterization of drug delivery systems for small molecules, proteins, and nucleic acids have grown well beyond the available budgetary restrictions of the CNM, with the DD&N becoming an integral part of the P30 effort. Our collaborative efforts have led to significant progress in novel therapeutic approaches for the treatment of glaucoma, optic nerve injury, retinopathy of prematurity, and dry eye. The DD&N module will continue to thrive and enable significant discoveries by the P30 collaborators.

项目概要-纳米技术药物输送和纳米技术（DD&N）模块是一个可用的技术资源威尔默眼科研究所的教员，通过持续和有针对性的药物输送，玻璃体内、结膜下或全身给药，以及开发新的成像技术。技术.在目前这段时间里，这些合作带来了许多NIH的赠款，出版物，许多专利授权，和重大的翻译工作，与多种治疗由威尔默P30团队开发的方法正在进行临床转化。DD&N需要利用威尔默眼科研究中心的专业知识、技术和资源，纳米医学（CNM）。威尔默的纳米医学中心是DD&N的锚模块，并已发展到七个教师，与超过15个教师在威尔默和更多的合作约翰霍普金斯的100多名教员。威尔默研究人员的需求（包括已成立的和早期的研究人员）用于开发和表征小分子的药物递送系统，蛋白质和核酸的增长远远超出了全国妇女委员会现有的预算限制，随着DD&N成为P30努力的一个组成部分。我们的共同努力，用于治疗青光眼，视神经损伤，早产儿视网膜病和干眼。DD&N模块将继续蓬勃发展， P30合作者的重大发现。